Valproate Therapy and Nonalcoholic Fatty Liver Disease

Annals of Neurology

Volumn 55, Issue 5, 2004, Pages 729-732

  Luef, Gerhard J ^a   Waldmann, Markus ^a   Sturm, Wolfgang ^b   Naser, Anis ^a   Trinka, Eugen ^a   Unterberger, Iris ^a   Bauer, Gerhard ^a   Lechleitner, Monika ^b  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CARBAMAZEPINE; INSULIN; VALPROIC ACID;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOGRAPHY; EPILEPSY; FEMALE; HUMAN; INSULIN RESISTANCE; LIVER FATTY DEGENERATION; MALE; NONALCOHOLIC FATTY LIVER DISEASE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; CARBAMAZEPINE; CHI-SQUARE DISTRIBUTION; EPILEPSY; FATTY LIVER; FEMALE; HUMANS; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC; VALPROIC ACID;

EID: 2142714501     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20074     Document Type: Article

References (20)

1. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002;16:695-714.
2. Biton V, Mirza W, Montsouris G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;56:172-177.
3. McLaughlin DB, Eadie MJ, Parker-Scott SL, et al. Valproate metabolism during valproate-associated hepatotoxicity in a surviving adult patient. Epilepsy Res 2000;41:259-268.
4. Luef G, Abraham I, Haslinger M, et al. Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women. J Neurol 2002;249:835-841.
5. Isojärvi JI, Laatikainen TJ, Knip M, et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-584.
6. Isojärvi JI, Rattya J, Myllyla VV, et al. Valproate, lamotrigine, and insulin mediated risks in women with epilepsy. Ann Neurol 1998;43:446-451.
7. Angulo P. Non-alcoholic fatty liver disease. N Engl J Med 2002;346:1221-1226.
8. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease. A feature of the metabolic syndrome. Diabetes 2001;50:1-7.
9. Reaven G. Metabolic syndrome. Pathophysiology and implication for management of cardiovascular disease. Circulation 2002;106:286-288.
10. Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol 2002;17:1136-1143.
11. Yang SQ, Lin HZ, Lane MD, et al. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 1997;94:2557-2562.
12. Patsch W, Brown SA, Morrisett J, et al. A dual precipitation method evaluated for measurement of cholesterol in high-density lipoprotein HDL2 and HDL3 in human plasma. Clin Chem 1989;5:265-270.
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
14. Matthews DR, Hosker JK, Radenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell-function from fasting plasma glucose and insulin concentrations in men. Diabetologia 1985;28:412-419.
15. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in non-alcoholic fatty liver disease. Gastroenterology 2002;123:745-750.
16. Luef G, Lechleitner M, Bauer G, et al. Valproic acid modulates islet cell insulin secretion: a possible mechanism of weight gain in epilepsy patients. Epilepsy Res 2003;55:53-58.
17. Powell-Jackson PR, Tredger JM, William SR. Hepatotoxicity to sodium valproate. A review. Gut 1984;25:673-681.
18. Stiemer B. Morphological evaluation of steatosis in morphological cultures (MDCK cells) after treatment with gentamycin and valproic acid. Histol Histopathol 1984;4:421-428.
19. Joy D, Thava VP, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol 2003;15:539-554.
20. Fichsel H. Effects of different anticonvulsive drugs on liver enzymes. Acta Neurol Scand 1980;62:108.